Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy

HIV Medicine

Volumn 14, Issue 4, 2013, Pages 241-246

  Gasser, O ^a,b   Brander, C ^c,d   Wolbers, M ^e,f   Brown, N V ^a   Rauch, A ^g   Gunthard H F ^h   Battegay, M ^b,i   Hess, C ^b   Bernasconi, E ⁱ   Boni J ⁱ   Bucher, H C ⁱ   Burgisser P ⁱ   Calmy, A ⁱ   Cattacin, S ⁱ   Cavassini, M ⁱ   Dubs, R ⁱ   Egger, M ⁱ   Elzi, L ⁱ   Fischer, M ⁱ   Flepp, M ⁱ   Fontana, A ⁱ   Francioli, P ⁱ   Furrer, H ⁱ   Fux, C A ⁱ   Gorgievski, M ⁱ   Gunthard H ⁱ   Hirsch, H H ⁱ   Hirschel, B ⁱ   Hosli I ⁱ   Kahlert, C ⁱ   Kaiser, L ⁱ   Karrer, U ⁱ   Kind, C ⁱ   Klimkait, T ⁱ   Ledergerber, B ⁱ   Martinetti, G ⁱ   Muller N ⁱ   Nadal, D ⁱ   Paccaud, F ⁱ   Pantaleo, G ⁱ   Regenass, S ⁱ   Rickenbach, M ⁱ   Rudin, C ⁱ   Schmid, P ⁱ   Schultze, D ⁱ   Schupbach J ⁱ   Speck, R ⁱ   de Tejada, B M ⁱ   Taffe P ⁱ   Telenti, A ⁱ   Trkola, A ⁱ   Vernazza, P ⁱ   Weber, R ⁱ   Yerly, S ⁱ   more..

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ NONE

Author keywords

Antiretroviral therapy; HIV specific T cells; T cell dynamics

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON;

ARTICLE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEOMICS; RETROSPECTIVE STUDY; T LYMPHOCYTE; VIRUS LOAD;

EID: 84874526749     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01040.x     Document Type: Article

References (19)

1. Hammer SM, Squires KE, Hughes MD etal. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
2. Staszewski S, Morales-Ramirez J, Tashima KT etal. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-1873.
3. Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 2001; 75: 6508-6516.
4. Ogg GS, Jin X, Bonhoeffer S etal. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73: 797-800.
5. Weekes MP, Wills MR, Sissons JG, Carmichael AJ. Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy. Immunology 2006; 118: 25-38.
6. Lu W, Andrieu JM. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 2000; 96: 250-258.
7. Cohort Profile. The Swiss HIV Cohort Study. Int J Epidemiol 2009; 30: 30.
8. Frahm N, Korber BT, Adams CM etal. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78: 2187-2200.
9. Bihl FK, Loggi E, Chisholm JV, 3rd etal. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". J Transl Med 2005; 3: 20.
10. Wittkowski KM. Friedman-type statistics and consistent multiple comparisons for unbalanced designs with missing data. J Am Stat Assoc 1988; 83: 1163-1170.
11. Brenchley JM, Price DA, Schacker TW etal. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
12. Hazenberg MD, Stuart JW, Otto SA etal. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-255.
13. Gagnon J, Ramanathan S, Leblanc C, Cloutier A, McDonald PP, Ilangumaran S. IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. J Immunol 2008; 180: 7958-7968.
14. Zeng R, Spolski R, Finkelstein SE etal. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005; 201: 139-148.
15. Autran B, Carcelain G, Li TS etal. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
16. Mollet L, Li TS, Samri A etal. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol 2000; 165: 1692-1704.
17. Pakker NG, Notermans DW, de Boer RJ etal. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4: 208-214.
18. Kim H, Perelson AS. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol 2006; 2: e135.
19. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.